ANGLE PLC (LON:AGL, OTCQX:ANPCY) said blood donations have restarted to support its US Food & Drug Administration analytical studies, while patient enrolment to its ovarian cancer test has also recommenced.
The developer of the Parsortix liquid biopsy system said it hoped to complete the work required for the FDA submission in the third quarter subject to the “inherent uncertainties” caused by the coronavirus lockdown.
Patient enrolment for ANGLE's ovarian cancer clinical verification study, which is being carried out in the US, will be complete by the end of the calendar year, investors were told.
“This has taken a major effort by all our team and collaborators and I thank them for their work to enable this,” said chief executive Andrew Newland.
“We are looking forward to making our FDA submission and completing our ovarian cancer study as soon as possible.”
He added that the lockdown had highlighted “major flaws” in cancer diagnosis and treatment that are overly dependent on surgical intervention.
“ANGLE is aiming to help address these issues through a simple blood test that can even be administered in the patient's own home,” he went on.
“We see this as a potential future contribution to the many issues arising from the COVID-19 lockdown for cancer patients and thank our shareholders for their patience and understanding whilst some of our work has been delayed during lockdown."